You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

 

Online download statistics by month:

Online download statistics by month: October 2020 to July 2025

AbstractFullPdf
Oct 202026126176
Nov 202018118052
Dec 2020878733
Jan 2021747437
Feb 2021303020
Mar 2021505023
Apr 2021535342
May 2021494921
Jun 2021393817
Jul 2021414110
Aug 2021333319
Sep 2021323214
Oct 2021727250
Nov 2021545544
Dec 2021454620
Jan 2022373819
Feb 2022313330
Mar 2022424316
Apr 2022414317
May 2022505122
Jun 2022424419
Jul 2022364219
Aug 202234359
Sep 2022495432
Oct 2022465023
Nov 2022454626
Dec 2022343523
Jan 2023292921
Feb 2023616226
Mar 2023292911
Apr 2023262616
May 2023222212
Jun 202321215
Jul 2023292919
Aug 2023262612
Sep 2023303012
Oct 2023272721
Nov 2023252516
Dec 2023363618
Jan 2024343519
Feb 2024444520
Mar 2024272759
Apr 2024252726
May 2024343530
Jun 2024373624
Jul 2024535436
Aug 2024252615
Sep 2024242526
Oct 2024393924
Nov 2024353722
Dec 2024555825
Jan 2025545438
Feb 2025474923
Mar 2025596036
Apr 2025919440
May 2025444529
Jun 2025363630
Jul 2025110
Total271327601444